Localized Bladder Cancer 2026 UPDATE

In this episode of Two Onc Docs, Sam and Kareen provide a comprehensive update on localized bladder cancer as of 2026, covering histology, diagnosis, staging, and evolving treatment paradigms. The discussion begins with the most common type—urothelial carcinoma—and delves into variant histologies like squamous, adenocarcinoma, plasmacytoid, and small cell, each with distinct risk factors and treatment approaches. The episode emphasizes the critical importance of muscle presence in biopsy specimens and outlines staging for non-muscle invasive bladder cancer (Ta, Tis, T1), highlighting BCG induction and maintenance as standard for high-risk cases. For BCG-refractory disease, novel intravesical therapies like netoferogen ferodenovec and nogapendaking alpha with BCG, along with systemic pembrolizumab, are now available. For muscle-invasive bladder cancer, the standard of care has evolved: cisplatin-eligible patients now receive neoadjuvant GEMSYS with duralumab (based on the Niagara trial), while the emerging EV-pembrolizumab regimen shows promising pathologic complete response rates but significant toxicity. For cisplatin-ineligible patients, EV-pembrolizumab is now approved and guideline-recommended based on EV303. Trimodal therapy with chemoradiation remains an option for carefully selected patients, with strict eligibility criteria. The episode concludes with key takeaways emphasizing treatment personalization based on histology, stage, and cisplatin eligibility, while noting that ctDNA monitoring remains investigational.